Bessemer Venture Partners III announced that it will sell only 130,000 shares of EPIX Medical, an MRI contrast agent developer. Based in Cambridge MA, EPIX main product currently under development is MS-325.
The original form filed with the Securities and Exchange Commission stated that Bessemer was planning to divest itself completely from EPIX, but the venture capital firm will retain 1,395,520 shares, EPIX said.
By AuntMinnie.com staff writersDecember 21, 2000
Copyright © 2000 AuntMinnie.com